Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029

Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information’s latest report, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.

Market Drivers & Opportunities

mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.

With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:

• What is the size and projected growth of the mPOC market?
• Which companies are leading the market, and how are they positioned?
• How is mPOC impacting traditional laboratory-based molecular testing?
• What regions and disease segments present the greatest opportunities?

• Market Sizing & Forecasts (2024-2029) – Revenue projections by technology, region, and disease area.
• Competitive Analysis – Market share breakdowns and insights into leading companies.
• Geographic Trends – Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
• Technology & Regulatory Landscape – Overview of CLIA-waived and moderate-complexity molecular platforms.


Scope

Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029 provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.

This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.

A Decade of mPOC Research Expertise

Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, offers critical insights to help you navigate and capitalize on this fast-growing segment.